Psychiatry Update: In Case You Missed It

Study finds most teens with first-episode psychosis stop antipsychotics within a year, boosting ER use; outpatient care and injectables may help.

Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.

Learn how clozapine, lithium, ketamine, and antidepressants fit into suicide prevention, from rapid crisis relief to long-term risk reduction.

Courts cite teen brain science to soften sentences; experts warn generalized neuroscience overreaches and adult responsibility stabilizes by 18 to 20.

Can hormones flag suicide risk in schizophrenia? Review links cortisol, thyroid and testosterone shifts—and clozapine/lithium pathways—to risk.

How VA clinicians treat veterans’ PTSD while managing suicide risk, using shared decisions, safety planning, and phase-based trauma therapies.

RADIANT phase 2 shows once-daily remlifanserin eases Alzheimer’s psychosis symptoms with placebo-like safety, advancing pivotal trials.

Discover how integrated psychotherapy—CBTp, family support, and relapse plans—boosts schizophrenia recovery alongside antipsychotics.